Back to results
US 2024/0216500 A1Published application
Respiratory virus combination vaccines
AssigneeModernaTX, Inc.
InventorsRaffael Nachbagauer, Carole Henry, Guillaume Stewart-Jones, Elisabeth Narayanan, Hamilton Bennett, Andrea Carfi
Life of this patent
Estimating the term…
Abstract
The disclosure provides combination mRNA vaccines for respiratory viruses, as well as methods of using the vaccines.
Claims189
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is an influenza virus antigen;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- and a lipid nanoparticle (LNP).
2 more elements
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is an influenza virus antigen;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- a fourth mRNA polynucleotide comprising an ORF encoding a fourth respiratory virus antigenic polypeptide from a fourth virus;
- and a lipid nanoparticle.
3 more elements
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is an influenza virus antigen;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- a fourth mRNA polynucleotide comprising an ORF encoding a fourth respiratory virus antigenic polypeptide from a fourth virus;
- a fifth mRNA polynucleotide comprising an ORF encoding a fifth respiratory virus antigenic polypeptide from a fifth virus;
- and a lipid nanoparticle.
4 more elements
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is an influenza virus antigen;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- a fourth mRNA polynucleotide comprising an ORF encoding a fourth respiratory virus antigenic polypeptide from a fourth virus;
- a fifth mRNA polynucleotide comprising an ORF encoding a fifth respiratory virus antigenic polypeptide from a fifth virus;
- a sixth mRNA polynucleotide comprising an ORF encoding a sixth respiratory virus antigenic polypeptide from a sixth virus;
- and a lipid nanoparticle.
5 more elements
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is an influenza virus antigen;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- a fourth mRNA polynucleotide comprising an ORF encoding a fourth respiratory virus antigenic polypeptide from a fourth virus;
- a fifth mRNA polynucleotide comprising an ORF encoding a fifth respiratory virus antigenic polypeptide from a fifth virus;
- a sixth mRNA polynucleotide comprising an ORF encoding a sixth respiratory virus antigenic polypeptide from a sixth virus;
- a seventh mRNA polynucleotide comprising an ORF encoding a seventh respiratory virus antigenic polypeptide from a seventh virus;
- and a lipid nanoparticle.
6 more elements
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is an influenza virus antigen;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- a fourth mRNA polynucleotide comprising an ORF encoding a fourth respiratory virus antigenic polypeptide from a fourth virus;
- a fifth mRNA polynucleotide comprising an ORF encoding a fifth respiratory virus antigenic polypeptide from a fifth virus;
- a sixth mRNA polynucleotide comprising an ORF encoding a sixth respiratory virus antigenic polypeptide from a sixth virus;
- a seventh mRNA polynucleotide comprising an ORF encoding a seventh respiratory virus antigenic polypeptide from a seventh virus;
- an eighth mRNA polynucleotide comprising an ORF encoding a eighth respiratory virus antigenic polypeptide from a eighth virus;
- and a lipid nanoparticle.
7 more elements
A multivalent RNA composition, comprising a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, from a first virus;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- wherein the multivalent RNA composition comprises greater than 40% polyA-tailed RNAs and/or each of the first, second and/or third mRNA polynucleotides is different in length from one another by at least 100 nucleotides.
1 more element
A multivalent RNA composition, comprising 2-15 mRNA polynucleotides, each comprising a distinct open reading frame (ORF) encoding a respiratory virus antigenic polypeptide, wherein each mRNA polynucleotide comprises one or more non-coding sequences in an untranslated region (UTR), optionally a 5′ UTR or 3′ UTR.
A multivalent RNA composition, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, from a first virus;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and
- a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- wherein at least one of the respiratory virus antigenic polypeptides is derived from a naturally occurring antigen or a stabilized version of a naturally occurring antigen and further comprising an mRNA polynucleotide encoding a structurally altered variant respiratory virus antigenic polypeptide, wherein the structurally altered variant is a structurally altered variant of any one of the first, second, or third respiratory virus antigenic polypeptides, and
- wherein the second and third viruses are different from one another and from the influenza virus.
3 more elements
A multivalent RNA composition, comprising
- 5 to 15 messenger ribonucleic acid (mRNA) polynucleotides, each comprising an open reading frame (ORF) encoding a distinct respiratory virus antigenic polypeptide, wherein the respiratory virus antigenic polypeptides are derived from three different viral families;
- and a lipid nanoparticle.
A multivalent RNA composition, comprising
- a set of at least 6 messenger ribonucleic acid (mRNA) polynucleotides, each comprising an open reading frame (ORF) encoding a respiratory virus antigenic polypeptide from a first, second or third virus;
- wherein the composition comprises a ratio of mRNA polynucleotides encoding respiratory virus antigenic polypeptides of 4:1:1, 4:2:2, 4:2:1, 4:3:2, 4:3:3, 4:3:2, or 4:2:2 from the first virus to the second virus to the third virus.
The multivalent RNA composition 113, wherein the LNP comprises a molar ratio of 20-60% ionizable amino lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.
A method for vaccinating a subject, comprising:
- administering to the subject a combination vaccine, wherein the combination vaccine comprises a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide from a first virus;
- a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus;
- and a third mRNA polynucleotide comprising an ORF encoding a third respiratory virus antigenic polypeptide from a third virus;
- wherein each of the first, second and third viral families is different from one another.
1 more element
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is an influenza virus antigen from the influenza virus family Orthomyxoviridae and a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus, wherein the second respiratory virus antigenic polypeptide is an antigen from viral family Paramyxoviridae, and a lipid nanoparticle.
A combination vaccine, comprising
- a first messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a first respiratory virus antigenic polypeptide, wherein the first respiratory virus antigenic polypeptide is a coronavirus antigen from the viral family Coronaviridae and a second mRNA polynucleotide comprising an ORF encoding a second respiratory virus antigenic polypeptide from a second virus, wherein the second respiratory virus antigenic polypeptide is an antigen from viral family Paramyxoviridae, and a lipid nanoparticle (LNP).
Dependencies are inferred from the claim text.